Urinary tract infections are a common patient experience, particularly for women. The typical symptoms of such infections may include dysuria, increased urinary frequency, and hematuria. A urinary tract infection in an otherwise healthy, nonpregnant individual with a structurally normal urinary tract is commonly referred to as an uncomplicated urinary tract infection. 

Today, we are taking a look at the latest information regarding uncomplicated urinary tract infections in relation to clinical guidance, FDA approvals, and ongoing clinical trials.

Current Clinical Guidance Related to Uncomplicated Urinary Tract Infection

The American Urolo//gical Association (AUA), Society of Urodynamics Female Pelvic Medicine & Urogenital Reconstruction (SUFU), and the Canadian Urological Association (CUA) published a guideline in September 2025 that focuses on recurrent uncomplicated urinary tract infections in women. Additionally, the American College of Radiology (ACR) and National Institute for Health and Care Excellence (NICE) both published guidance on urinary tract infections that include uncomplicated urinary tract guidance within the past five years.

Recent FDA Approvals for Uncomplicated Urinary Tract Infections

Below are the medications and therapies recently approved by the FDA that we anticipate being incorporated into future clinical guidelines: 

  • Blujepa (gepotidacin)
    • GlaxoSmithKline
    • Approved: March 2025
    • Blujepa is indicated for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older.
  • Orlynvah (sulopenem etzadroxil and probenecid)
    • Iterum Therapeutics
    • Approved: October 2024
    • Orlynvah is indicated for the treatment of uncomplicated urinary tract infections (uUTIs) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options.
  • Pivya (pivmecillinam)
    • Utility Therapeutics
    • Approved: April 2024
    • Pivya (generic) is indicated for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
Recently Completed Phase 3 Clinical Trial

The following is a recently completed, Phase 3 clinical trial based in the United States that we anticipate may impact future uncomplicated urinary tract infection clinical guidelines.

Don't miss out on our other urology content. Sign up for alerts to keep up with the latest guidelines and insights.